Pipeline

Our mission is to develop breakthrough rare disease therapies for the patients and families who need them.

Oak Hill Bio Pipeline
CANDIDATE
INDICATION
MODALITY
PRE-CLINICAL
PHASE 1
PHASE 2
PHASE 3
ANTICIPATED MILESTONES
Rugonersen
Angelman
Syndrome
Antisense Oligonucleotide
Phase 3 start mid-year 2026
OHB-607
Complications
of Prematurity
Recombinant Protein
With Chiesi
Phase 2b trial ongoing
OHB-401
Diabetic
Macular Edema
Small Molecule
Phase 1 start in mid-2027
Oak Hill Bio Pipeline
Candidate
Anticipated Milestones
Rugonersen
Phase 3 start mid-year 2026
OHB-607
With Chiesi
Phase 2b trial restarted
Q2 2024
OHB-401
Phase 1 start in mid-2026
PROGRAMS

Rugonersen

Antisense oligonucleotide for Angelman syndrome.
Learn More →